Keros Therapeutics (KROS) Capital Expenditures (2019 - 2025)
Keros Therapeutics posted quarterly Capital Expenditures of -$1.4 million for Q4 2025, down 588.58% year-on-year from $289000.0 in Q4 2024, and down 200.64% on a QoQ basis from $1.4 million in Q3 2025.
Keros Therapeutics (KROS) has 7 years of Capital Expenditures data on file, last reported at -$1.4 million in Q4 2025.
- For the quarter ending Q4 2025, Capital Expenditures fell 588.58% year-over-year to -$1.4 million; the trailing twelve-month figure through Dec 2025 stood at $5000.0 (down 99.74% YoY), and the FY2025 full-year result was $5000.0, down 99.74% from the prior year.
- Capital Expenditures for Q4 2025 stood at -$1.4 million, down from $1.4 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.6 million in Q3 2024 and bottomed at -$1.4 million in Q4 2025.
- The 5-year median for Capital Expenditures is $159000.0 (2021), against an average of $252631.6.
- The widest annual swing landed in 2021, when Capital Expenditures soared 2471.43%; it then tumbled 11836.36% in 2023.
- A 5-year view of Capital Expenditures shows it stood at $159000.0 in 2021, then surged by 672.33% to $1.2 million in 2022, then plunged by 56.11% to $539000.0 in 2023, then sank by 46.38% to $289000.0 in 2024, then slumped by 588.58% to -$1.4 million in 2025.
- The last three Capital Expenditures figures came in at -$1.4 million (Q4 2025), $1.4 million (Q3 2025), and -$551000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - | -1.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.41 Mn |
| Dec 31, 2025 | -1.41 Mn |
| Sep 30, 2025 | 1.40 Mn |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | -551,000.00 |
| Jun 30, 2025 | -551,000.00 |
| Mar 31, 2025 | 565,000.00 |
| Mar 31, 2025 | 565,000.00 |
| Dec 31, 2024 | 289,000.00 |
| Dec 31, 2024 | 289,000.00 |
| Sep 30, 2024 | 1.56 Mn |
| Sep 30, 2024 | 1.56 Mn |
| Jun 30, 2024 | -146,000.00 |
| Jun 30, 2024 | -146,000.00 |
| Mar 31, 2024 | 230,000.00 |
| Mar 31, 2024 | 230,000.00 |
| Dec 31, 2023 | 539,000.00 |
| Dec 31, 2023 | 539,000.00 |
| Sep 30, 2023 | -1.31 Mn |
| Sep 30, 2023 | -1.31 Mn |
| Jun 30, 2023 | 1.35 Mn |
| Jun 30, 2023 | 1.35 Mn |
| Mar 31, 2023 | 21,000.00 |
| Mar 31, 2023 | 21,000.00 |
| Dec 31, 2022 | 1.23 Mn |
| Dec 31, 2022 | 1.23 Mn |
| Sep 30, 2022 | -11,000.00 |
| Sep 30, 2022 | -11,000.00 |
| Jun 30, 2022 | -63,000.00 |
| Jun 30, 2022 | -63,000.00 |
| Mar 31, 2022 | 87,000.00 |
| Mar 31, 2022 | 87,000.00 |
| Dec 31, 2021 | 159,000.00 |
| Dec 31, 2021 | 159,000.00 |
| Sep 30, 2021 | 145,000.00 |
| Sep 30, 2021 | 145,000.00 |
| Jun 30, 2021 | 720,000.00 |
| Jun 30, 2021 | 720,000.00 |
| Dec 31, 2020 | 60,000.00 |
| Dec 31, 2020 | 60,000.00 |
| Sep 30, 2020 | 30,000.00 |
| Sep 30, 2020 | 30,000.00 |
| Jun 30, 2020 | 28,000.00 |
| Jun 30, 2020 | 28,000.00 |
| Mar 31, 2020 | 176,000.00 |
| Mar 31, 2020 | 176,000.00 |
| Dec 31, 2019 | 18,000.00 |
| Dec 31, 2019 | 18,000.00 |
| Sep 30, 2019 | 82,000.00 |
| Sep 30, 2019 | 82,000.00 |
| Jun 30, 2019 | 171,000.00 |
| Jun 30, 2019 | 171,000.00 |